1-2 of 2
Lukáš Stejskal, MD
Close
Sort by
Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.
Journal: Blood
Blood (2019) 134 (Supplement_1): 5905.
https://doi.org/10.1182/blood-2019-126395
Published: 2019
Journal Articles

Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)

Jiri Minarik, MD PhD, Tomas Pika, MD PhD, Jakub Radocha, Alexandra Jungova, Jan Straub, MD, Tomas Jelinek, MD, Ludek Pour, MD, Petr Pavlicek, MD, Martin Mistrik, MD PhD, Lucie Brožová, MSc, Petra Krhovska, Katerina Machalkova, Pavel Jindra, MD PhD, Ivan Spicka, MD PhD Prof, Hana Plonkova, MD, Martin Stork, MD, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, MD, Lukáš Stejskal, MD, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, MD, Vladimir Maisnar, MD PhD MBA, Roman Hajek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3139.
https://doi.org/10.1182/blood-2019-128865
Published: 2019